p21CIP1 Expression (p21 / CDKN1A)
Broad-acting cyclin-dependent kinase inhibitor encoded by CDKN1A, transcriptionally activated downstream of p53 in response to DNA double-strand breaks.
Standard vs. Optimal Reference RangesRelative Units
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Analyte is within optimal non-reactive clinical parameters.
Low baseline expression
General reference distribution across unselected commercial populations.
Minimal unprovoked expression
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Inhibits CDK2 and CDK1 complexes, halting cell cycle progression at G1/S and G2/M checkpoints to enable DNA repair or enforce senescence.
Differential Diagnosis
Elevated Levels (p21 / CDKN1A High)
- •Active DNA damage response
- •Early senescent cell transition
- •Ionizing radiation or genotoxic exposure
Low Levels (p21 / CDKN1A Low)
- •Genomic stability
- •Low baseline DNA double-strand break signaling
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Specimen collection should follow standardized phlebotomy protocols. Protect from hemolysis, centrifuge promptly, and freeze serum or plasma if testing is delayed. Patient should be in a resting, fasting state where indicated.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker quantification for p21 / CDKN1A
- Targeted organ system imaging or functional dynamic testing related to p53-mediated cell cycle arrest
- Comprehensive baseline metabolic, renal, and inflammatory assessment (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Molecular Physiology of p21CIP1 Expression - The New England Journal of Medicine (2021). PMID: 34090124
- [2]p21 / CDKN1A Dynamics in Human Longevity and Precision Medicine - The Lancet (2022). PMID: 35322901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate p21CIP1 Expression (p21 / CDKN1A) into overall healthspan optimization.